FDA gives special clearance for H1N1 claims from Quidel and Meridian
This article was originally published in Clinica
Two more rapid flu tests can be used to detect the H1N1 pandemic virus, adding to the recent glut of approvals for similar diagnostics. The US FDA has granted special 510(k) clearance for updated labelling claims for Quidel's QuickVue Influenza A+B test and Meridian Bioscience's Tru Flu, highlighting their sensitivity to H1N1. Meridian (River Hills Drive, Cincinnati) will update the Tru Flu package insert to say that it has shown "analytical activity" to two H1N1 flu strains, while Quidel (San Diego, California) will update the QuickVue label to include "reactivity with culture isolates of the 2009 H1N1 influenza A virus". Neither test's performance with clinical specimens has been proven. QuickVue and Tru Flu provide results in 10 minutes and 15 minutes, respectively.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.